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Introduction: Fibrotic interstitial lung diseases (ILDs) are the first indication for lung
transplantation (LT). Telomere dysfunction has been associated with poor post-transplant
outcomes. The aim of the study was to evaluate the morbi-mortality and quality of life in
fibrotic ILDs after lung transplant depending on telomere biology.
Methods: Fibrotic ILD patients that underwent lung transplant were allocated to
two arms; with or without telomere dysfunction at diagnosis based on the telomere
length and telomerase related gene mutations revealed by whole-exome sequencing.
Post-transplant evaluation included: (1) short and long-term mortality and complications
and (2) quality of life.
Results: Fifty-five percent of patients that underwent LT carried rare coding
mutations in telomerase-related genes. Patients with telomere shorteningmore frequently
needed extracorporeal circulation and presented a higher rate of early post-transplant
hematological complications, longer stay in the intensive care unit (ICU), and a higher
number of long-term hospital admissions. However, post-transplant 1-year survival was
higher than 80% regardless of telomere dysfunction, with improvement in the quality of
life and oxygen therapy withdrawal.
Conclusions: Post-transplant morbidity is higher in patients with telomere dysfunction
and differs according to elapsed time from transplantation. However, lung transplant
improves survival and quality of life and the associated complications are manageable.
Keywords: interstitial lung disease, pulmonary fibrosis, genetics, telomere shortening, telomere disorders, lung
transplantation
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INTRODUCTION
Fibrotic interstitial lung diseases (ILDs) are comprised of
parenchymal lung disorders with progressive, irreversible fibrosis
that present a devastating clinical course (1). Idiopathic
pulmonary fibrosis (IPF) is the most lethal fibrotic ILD. Although
new anti-fibrotic medications slow disease progression, lung
transplantation (LT) remains the treatment option that improves
lung function and survival in those cases that can benefit from
this procedure (2). After several years with an increasing trend,
fibrotic ILD is often now reported as the first indication for
LT (3).
In previous studies, pulmonary fibrosis has been linked to
aging and repair defects, especially telomere attrition (4–14).
Rare coding mutations in telomere-maintenance genes (TERT,
TERC, PARN, RTEL1, DKC1, TINF2, NAF1, ACD, NOP10,
NHP2) and telomere shortening have been identified in different
fibrotic ILDs, irrespective of family aggregation (4–6, 9, 10,
12, 15, 16). Regardless of gene mutations and ILD diagnoses
(17), telomere shortening has been associated with disease
progression, reduced survival, and poor LT outcomes (18, 19).
Telomeric disease onset frequently appears in young adults;
therefore, LT may be necessary in most patients (18). However,
some reports have shown a high morbidity and mortality
related to LT in fibrotic ILD cases with telomere defects (20–
25). Furthermore, increased immunosuppressive drug-related
toxicities have also been reported (26, 27), especially during
post-transplant prophylaxis regimens (20–22), probably due to
the associated T cell immunodeficiency (28). Nevertheless, most
studies evaluating the effect of telomere dysfunction in LT lack
a control group that allow to differentiate those effects only
attributed to this biological defect (20–24).
A systematic assessment of telomere length in the pre-
transplant study could be useful for optimizing LT protocol
among fibrotic ILD cases. However, limited data exists about the
LT in pulmonary fibrosis depending on telomere biology and
the different technical interventional approaches. The aim of the
study was to compare the morbidity, mortality, and quality of




This prospective observational study included 20 patients from
the ILD Unit of Hospital Universitari de Bellvitge (HUB) with
any form of fibrotic ILD that underwent LT at the Hospital
Universitari Vall d’Hebrón, in Barcelona. The Ethics Committee
of HUB approved the study and all patients provided written
informed consent before inclusion. A telomere genetic study was
performed at the moment of diagnosis. Diagnosis was performed
following the international clinical guidelines for ILDs (29–31).
Patients were recruited at the time of referral to the LT evaluation,
with a post-transplant follow-up period of at least 3 months.
Patients were excluded if they did not consent to the telomere
genetic test.
Clinical data were prospectively recorded from patient
inclusion. Surgical, post-surgical procedure, and management
protocols were blinded to the laboratory tests and followed
national and international guidelines (32, 33). The Lung
Allocation Score (LAS) was used to assess the allocating process
of donated lungs. The decision for unilateral vs. bilateral lung
transplant was based on the presence of pulmonary hypertension
or microbiological colonization. In those cases, a bilateral
lung transplant was performed. A standard immunosuppression
regimen was initiated after LT and adjusted as tolerated. The
prophylaxis for cytomegalovirus (CMV) was initiated after
the surgical procedures in all patients, using ganciclovir 3–5
mg/kg/12 h during the Intensive Care Unit (ICU) stay, followed
by valganciclovir 900 mg/day when oral intake was tolerated.
The treatment was maintained for 12 months in serum-negative
pre-transplant cases and 6 months for those serum-positive. The
post-transplant evaluation included: (1) type of complications
observed during the first 24 h, the first 30 days, and after the
first month; and, (2) assessment of the quality of life after 6
months of LT based on an improvement of forced vital capacity
(FVC) and health status questionnaires (K-BILD and ATAQ-
IPF), oxygen therapy withdrawal and declared independence for
daily life activities.
Telomere Genetic Studies
The telomere genetic study was performed at fibrotic ILD
diagnosis and consisted of: (1) a telomere length screening of
DNA isolated from mouth epithelial cells (oral swab) using a
commercial DNA isolation kit (Isohelix, Cell Projects Ltd.) (34)
and further validation based on DNA from peripheral blood; (2)
a sequencing analysis of the known telomere related-genes (TRG)
described so far as a cause of pulmonary fibrosis. The assessment
of telomere dysfunction in donors was unavailable in our study
due to the great inherent lung transplant technical difficulties.
Telomere Length Analysis
The relative telomere length was performed in the Instituto de
Investigaciones Biomédicas (CSIC/UAM) and initially assessed
by quantitative polymerase chain reaction (qPCR), as previously
described (19, 35, 36). Since telomere length changes with age,
a Z-score value was obtained to allow the comparisons of the
telomere length between individuals of different ages. The Z-
score compared the Telomere Shortening T/S ratio value in each
individual with the age-matched mean and standard deviation
(SD) of the values obtained in the controls. The Z-score below the
25th percentile of a normal distribution was considered as “short
telomere.” A severe telomere length reduction was identified
when Z-score was below the 10th percentile.
Telomere shortening was confirmed by telomere restriction
fragment (TRF) assay (TeloTAGGG Telomere Length Assay,
Roche) from peripheral blood DNA of each patient, as previously
described (36, 37) (Figure 1). A positive correlation (r =
0.689) was observed between the two sets of telomere length
measurements performed by either the qPCR on DNA extracted
from buccal cells or by the Southern Blot of blood DNA,
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FIGURE 1 | (A) Telomere length and qPCR essential primary data of all study patients: telomere length was measured, at diagnosis, from oral epithelium DNA,
through quantitative Polymerase Chain Reaction (qPCR) and Z-score was obtained as described in Methods section. The qPCR determines the ratio of telomere (T)
repeat copy number to single-copy (S) gene (36B4) copy number (T/S ratio), as compared with a reference DNA sample. The Z-score below the 25th percentile of a
normal distribution was considered “telomere shortening.” (B) qPCR validation through TRF Southern Blot: telomere shortening was validated in each patient from
blood DNA by telomere restriction fragment (TRF) Southern Blot analysis (TeloTAGGG Telomere Length Assay, Roche), which is considered the gold standard to
determine telomere length. A representative southern blotting image is shown. The absolute telomere length of the telomeres in blood DNA samples from controls (C
lanes) and patients (F lanes) was measured (C) Distribution of the absolute telomere length (kb) obtained by TRF Southern Blot in blood samples of controls and
patients vs. age (years).
in accordance with a previous study published by Demanelis
et al. (38).
The control population for telomere Z-score calculation
consisted of 243 healthy subjects, with no respiratory disease,
cancer, or any degenerative disorders such as diabetes,
hematological, liver, or kidney disease. Other characteristics
from the control population were described previously (19).
Oral swab and peripheral blood sample were also processed in
controls for DNA isolation. The same protocol described above
was followed to process control DNA samples.
Sequencing Analysis and Identification of
Rare Coding Mutations in TRG
Patients with telomere shortening were subjected to whole-
exome sequencing to obtain genetic variation at the telomere
maintenance genes. Whole-exome sequences were obtained
by the Instituto Tecnológico y de Energías Renovables (ITER).
Briefly, DNA samples were processed with Nextera DNA
Exome Kit with dual indexes following the manufacturer’s
recommendations (Illumina Inc., San Diego, CA). Library sizes
were evaluated on a TapeStation 4200 (Agilent Technologies,
Santa Clara, CA) and their concentration determined by the
Qubit dsDNA HS Assay (Thermo Fisher, Waltham, MA).
Samples were sequenced along with 1% of a PhiX control V3 to
an average depth >50X (after removal of duplicate reads) on a
HiSeq 4000 instrument (Illumina Inc.) with paired-end 75-base
reads. Reads were preprocessed with bcl2fastq v2.18 and aligned
(>99.70% of reads were mapped) to hg19 with BWA-MEM
0.7.15-r1140 (39). BAM files were processed with SAMtools
v1.3 (40) and Picard v2.10.10, and small insertion/deletions
(indels) and single nucleotide variants (SNVs) were identified
with the HaplotypeCaller following the Best Practices workflow
recommendations for germline variant calling in GATK
(v3.8) (41). Detected variants were annotated for frequency in
gnomAD, function and pathogenic potential with SnpEff v4.3
(42) and ANNOVAR v18.04.16 (43) based on data from different
sources. We simplified the prioritization of pathogenicity
potential by focusing only on the results in the previously-
known TRG: TERT (chr5:1,253,262–1,295,184), TERC
(chr3:169,482,308–169,482,848), DCK1 (chrX:153,991,031–
154,005,964), PARN (chr16:14,529,558–14,726,585), RTEL1
(chr20:62,289,163–62,328,416), TINF2 (chr14:24,708,849–
24,711,880), and TERF1 (chr8:73,921,097–73,960,357). Among
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the TRG set, we prioritized the variants that were likely to
alter the function of the encoded proteins based on a CADD
phred score >15 (standard threshold for deleteriousness) and
rareness in the population (<0.5% in genomAD). On those
patients that these criteria did not evidence a prioritized variant,
we opted for prioritizing one variant applying more liberal
filters but showing a predicted damage potential based on the
effect (frameshift, stop gain/loss, splice site, codon deletion,
non-synonymous change, etc.). Given the uncertainty in their
pathogenic potential, we will refer to the prioritized variants as
rare coding mutations thereafter.
Statistical Analysis
Categorical variables were presented as the number of cases and
percentages, while continuous variables were presented as the
mean and SD or median and the interquartile range (IQR). In
continuous variables, the group means were compared using
the Student’s t-test and the group medians were compared with
the Mann-Whitney U-test. Fisher’s exact test or a Pearson’s X2-
test were applied to assess the relationship between categorical
variables. Time until death was assessed using the Kaplan–Meier
estimator. Analyses were performed with R 3.4.0 (44). A p-value
<0.005 was considered statistically significant.
RESULTS
Patient Characteristics
From 274 fibrotic ILD patients that had been tested for telomere
attrition at diagnosis, 20 cases underwent LT from June 2013
to October 2018. Telomere attrition was identified in 12 (60%)
patients and rare coding mutations in TRG in 11 of them (55%
of the cohort) (Supplementary Table 1). Patients underwent
LT at a younger age if telomere dysfunction was present.
Idiopathic pulmonary fibrosis and FPF were the most frequent
diagnoses. The anti-fibrotic therapy was prescribed in 12 patients
at diagnosis (Table 1).
A similar pre-transplant functional status was reported for
patients with or without telomere dysfunction (Table 2). Oxygen
therapy was prescribed in all patients with telomere dysfunction
(n = 12, 100%), with a median time of prescription of 12.5
months (range 11.0–16.2); and in 7 (87.5%) patients without
telomere disorders with amedian prescription time of 9.0months
(range 7.5–12.5) (p = 0.090). The pre-transplant health status
questionnaires ATAQ and K-BILD were scored in the entire
patient series. Patients with telomere dysfunction presented a
worse pre-transplant health status compared to the patients
without telomere disorders, with a median ATAQ score of 108
(8.27) and a median K-BILD score of 22.5 (16.0), (p = 0.032 and
p= 0.036, respectively) (Table 2).
Regarding the LAS score, the patients with telomere disorders
had a median LAS of 43.1 (range 38.4–51.3) with no statistically
significant difference from patients without telomere dysfunction
(p= 0.283) (Table 2). Despite the median time from diagnosis to
the LT was lower in those cases with telomere dysfunction (p =
0.076), the time on the waiting list was similar among the patients
with and without telomere disorders (p= 0.877) (Table 2).
Surgical Procedure and Immediate
Post-surgery Requirements
Unilateral LT was performed in 14 (70.0%) cases. In both groups
of patients, with and without telomere disorders, unilateral LT
was the main choice.
Although no statistically significant differences were found
during the surgical procedure, more cases with telomere
dysfunction required extracorporeal circulation (ECC); among
four patients, three of them presented telomere dysfunction. A
longer time for ECC was registered for the telomere dysfunction
group (median 150min, range 122–244). The time of ischemia
was also longer for patients with telomere disorders (median
6.88 h, range 5.25–7.69) (Table 3).
Regarding the first 24 h after LT, 15% of overall cases
presented relevant complications, including hemodynamic
instability, phrenic or diaphragmatic paresis, hypovolemic
shock, thrombocytopenia, and primary graft dysfunction
(Supplementary Table 2). No significant differences were
observed by telomere dysfunction (p = 0.495) (Table 3).
However, mild hematological complications during the first 24 h
after LT were only reported in patients with telomere disorders
(Supplementary Table 2).
Concerning the ICU admission period, the average stay was
longer for patients with telomere dysfunction with a median
of 30.0 days [(range 7.75–40.8 days, p = 0.352)] (Table 3).
Time of respiratory support required, difficult weaning, and
tracheostomy did not differ significantly due to the presence of
telomere dysfunction (p= 1.000) (Table 3).
Complications and Morbidity After Lung
Transplant
We analyzed the complications reported and hospital admission
requirements after LT. More than one complication per patient
was reported regardless of telomere dysfunction (p= 1.000)
(Table 4). During the first month, complications were present
in 9 (81.8%) patients with telomere disorders, and in all
patients (n = 8, 100%) without (p = 0.485) (Table 4).
Renal failure was the main complication in the overall
population (Supplementary Table 3). A higher rate of primary
graft dysfunction and hypovolemic shock was more frequently
reported for patients with telomere dysfunction; while phrenic
or diaphragmatic paresis and hemodynamic instability were
more present in patients without. The main hematological
complication, thrombocytopenia, was only described in telomere
dysfunction group, although pre-transplant thrombocytopenia
was only present in one of those cases (Supplementary Table 3).
After the first month of LT, all patients with telomere
dysfunction (n = 11, 100%) and 7 (87.5%) patients without
telomere disorders had complications (p = 0.421). As shown in
Table 4, endocrine dysfunction and infections were predominant
in both groups. Chronic lung allograft dysfunction (CLAD)
and post-transplant CMV replication were higher in patients
without telomere alterations [n = 5 (62.5%) and n = 7, (87.5%)
respectively]. However, patients with telomere dysfunction
showed a lower rate of CMV negativity after Valganciclovir (n
= 4, 44.4%) with a higher rate of hematological complications
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TABLE 1 | Patient characteristics.
All patients (n = 20) With telomere
shortening (n = 12)
Without telomere
shortening (n = 8)
P-value
Age at lung transplant [years, mean (SD)] 56.6 (9.39) 51.8 (9.18) 63.8 (3.11) 0.001
Gender (n, %)
- Males 15 (75.0) 9 (75.0) 6 (75.0) 1.000
- Females 5 (25.0) 3 (25.0) 2 (25.0)
Smoking history at diagnosis (n, %):
- Non-smoker 3 (15.0) 2 (16.7) 1 (12.5) 1.000
- Current smoker 3 (15.0) 2 (16.7) 1 (12.5)
- Former smoker 14 (70.0) 8 (66.7) 6 (75.0)
Diagnosis (n, %):
- IPF 8 (40.0) 4 (33.3) 4 (50.0) 0.961
- FPF 8 (40.0) 5 (41.6) 3 (37.5)
- HP 1 (5.0) 0 (0.0) 1 (12.5)
- CPFE 1 (5.0) 1 (8.3) 0 (0.0)
- DIP 1 (5.0) 1 (8.3) 0 (0.0)
- CTD-ILD 1 (5.0) 1 (8.3) 0 (0.0)
Pre-transplant treatment (n, %):
- Pirfenidone 7 (35.0) 2 (16.6) 5 (62.5) 0.062
- Nintedanib 5 (25.0) 3 (25.0) 2 (25.0) 1.000
- Corticosteroids 4 (20.0) 2 (16.6) 2 (25.0) 1.000
- Corticosteroids + immunosuppressive drug 5 (25.0) 5 (41.6) 0 (0.0) 0.055
Telomere shortening (n, %):
- n, below 1st percentile 3 (25.0) 3 (25.0) 0 (0.0) NA
- n, below 10th percentile 4 (33.3) 4 (33.3) 0 (0.0)
- n, below 25th percentile 5 (41.7) 5 (41.7) 0 (0.0)
Relative telomere length [mean, (SD)] 1.13 (0.33) 0.95 (0.29) 1.40 (0.17) 0.001
Z-score [mean, (SD)] −1.15 (1.22) −1.83 (1.04) −0.006 (0.44) 0.001
Likely causal variants in telomere-maintenance genes (n =1 8) (n, %): 11 (55.0) 10 (83.3) 1 (12.5) NA
- RTEL1 5 (45.5) 5 (50.0) 0 (0.0)
- DKC1 2 (18.2) 2 (20.0) 0 (0.0)
- PARN 1 (09.1) 0 (0.0) 1 (100)
- TERT 3 (27.3) 3 (30.0) 0 (0.0)
IPF, idiopathic pulmonary fibrosis; FPF, familial pulmonary fibrosis; HP, hypersensivity pneumonitis; CPFE, combined pulmonary fibrosis and emphysema; DIP, desquamative interstitial
pneumonia; CTD-ILD, connective tissue disease-associated interstitial lung disease; NA, not applicable.
due to CMV treatment (n = 3, 33.3%) (Table 4). Long-term
complications are summarized in Supplementary Table 4. The
type of complications according to telomere dysfunction and
time after LT are summarized in Table 5.
Regarding hospital admissions after LT, patients with telomere
dysfunction presented more hospitalizations (p = 0.033) and 2.9
times higher risk for readmission [Incidence Rate Ratio of 2.91,
95%CI = 1.11–7.59, (p = 0.029)] (Table 4). Infections were the
main cause of readmission in both groups of patients (Table 6).
Survival and Quality of Life After Lung
Transplant
At the end of the study, 17 of 20 subjects (85%) survived after
transplantation: 10/12 with telomere dysfunction (83.3%) and 7/8
(87.5%) without. Survival after LT is represented in Figure 2A.
Patients with telomere shortening had a median post-transplant
follow-up period of 39 months (range of 27–50 months) with
two deaths reported. One subject died after bilateral LT due to
multi-organic failure in the first 24 h; and the other patient died
after 17 months of post-transplant follow-up due to stage IIIB
cervical squamous-cell carcinoma. Both had a telomere length
below the 10th percentile and one of them carried a rare coding
RTEL1 gene mutation (chr20:62317210). No TRG mutations
were identified in the other patient. The median post-transplant
follow-up period in patients without telomere dysfunction was
15 months (range of 12–19) with one death reported after 17
months of unilateral LT due to CLAD. The time from diagnosis
to LT was shorter in those cases with telomere dysfunction.
Therefore, we also analyzed survival from diagnosis to the end of
the study period. No significant differences were found between
both groups; 5 years (range 5–6 years) vs. 6 years (range 4–7
years), with and without telomere dysfunction, respectively.
Post-transplant quality of life assessment reported a significant
improvement in respiratory functional and health status for
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TABLE 2 | Pre-transplant functional status.
All patients (n = 20) With telomere
shortening (n = 12)
Without telomere
shortening (n = 8)
P-value
LAS [median, (Q1;Q3)] 40.3 (37.3;46.0) 43.1 (38.4;51.3) 39.1 (36.9;41.2) 0.283
Time from diagnosis to transplant [months, mean (SD)] 42.1 (32.1) 36.2 (36.7) 51.0 (23.3) 0.284
Time from diagnosis to transplant [months, median (Q1;Q3)] 33.1 (24.0;50.3) 26.5 (21.9;36.3) 51.2 (30.8;67.6) 0.076
Waiting list time [months, median (Q1;Q3)] 5.00 (1.75;8.00) 5.00 (2.75;7.25) 4.00 (1.00;9.25) 0.877
FVC [L, mean (SD)] 1.87 (0.44) 1.96 (0.39) 1.73 (0.50) 0.294
FVC [%, mean (SD)] 45.3 (11.1) 45.9 (13.8) 44.5 (5.92) 0.764
DLCO [%, mean (SD)] 22.8 (5.71) 21.2 (6.06) 24.7 (5.10) 0.255
Basal SatO2 <90% in WT6m [n, mean (SD)] 79.2 (5.76) 79.2 (5.14) 79.0 (6.97) 0.932
6-min walk test distance [n, mean (SD)] 292 (83.5) 274 (77.7) 319 (89.9) 0.267
Oxygen therapy (n, %) 19 (95) 12 (100) 7 (87.5) 0.400
Time with oxygen therapy before transplant [months, mean (SD)] 12.8 (5.55) 14.3 (6.02) 10.1 (3.63) 0.076
Time with oxygen therapy before transplant [months, median (Q1;Q3)] 12.0 (9.00;15.5) 12.5 (11.0;16.2) 9.00 (7.50;12.5) 0.090
ATAQ score [mean (SD)] 102 (13.3) 108 (8.27) 92.6 (14.4) 0.032
K-BILD score [mean (SD)] 28.4 (15.1) 22.5 (16.0) 36.7 (9.20) 0.036
LAS, lung allocation score; FVC, forced vital capacity; DLCO, diffusion capacity for carbon monoxide; LT, lung transplant.
TABLE 3 | Surgical technique and immediate post-operative requirements.
All patients (n = 20) With telomere
shortening (n = 12)
Without telomere
shortening (n = 8)
P-value
Type of lung transplant (n, %): 1.000
- Unilateral 14 (70.0) 8 (66.7) 6 (75.0)
- Bilateral 6 (30.0) 4 (33.3) 2 (25.0)
Ischemia time [h, mean (SD)] 6.61 (2.82) 6.86 (2.55) 6.23 (3.33) 0.658
Ischemia time [h, median (Q1;Q3)] 6.42 (4.75;7.69) 6.88 (5.25;7.69) 5.42 (4.22;6.83) 0.354
Extracorporeal circulation need (n, %) 4 (20.0) 3 (25.0) 1 (12.5) 0.619
Extracorporeal circulation time [min, median (Q1;Q3)] 122 (88.0;197) 150 (122;244) 70.0 (70.0;70.0) 0.180
Stay in ICU [days, median (Q1;Q3)] 22.0 (7.50;36.5) 30.0 (7.75;40.8) 17.0 (7.00;22.5) 0.352
Post-operative complications in the first 24 h (n, %) 18 (90.0) 10 (83.3) 8 (100) 0.495
Difficult weaning (n, %) (n = 19) 10 (52.6) 6 (54.5) 4 (50.0) 1.000
Tracheostomy (n, %) (n = 19) 10 (52.6) 6 (54.5) 4 (50.0) 1.000
all patients. The mean FVC increase after LT for the entire
study population was 0.55 L (p = 0.0003) [95%CI: 0.21–0.89].
As shown in Figure 3, pre-transplant FVC-values (L) and the
absence of family aggregation significantly influenced the post-
transplant FVC-value (L) (p = 0.007, respectively). Regarding
the health status, a significant improvement was reported overall
through ATAQ-IPF and K-BILD scores, with p < 0.001 for both
questionnaires. No differences in ATAQ-IPF and K-BILD post-
transplant scores were found in telomere dysfunction patient
group (Table 7). Likewise, no differences were found for declared
daily life activity independence and active life after LT among
patients with and without telomere disorders. Nine out of 10
(90%) patients with telomere dysfunction reported daily life
activity independence, and 6 out of 10 (60%) had an active life
(p= 1.000). In addition, oxygen therapy withdrawal was possible
in 16 out of 17 (94.1%) patients of the overall population: 9 out
of 10 (90.0%) with telomere dysfunction and 7 out of 7 (100%)
without it (Table 7).
Lung Transplant in Familial Pulmonary
Fibrosis
Family aggregation was reported in 8 (40.0%) patients and
telomere shortening was present in 5 (62.5%) of them. Rare
coding TRG mutations were identified in 4 out of 8 (50.0%)
patients. A similar pre-transplant functional status was reported
according to family aggregation without differences in the
time from diagnosis to the LT (Supplementary data Table 5).
FPF cases presented a non-significant higher rate of difficult
weaning and a greater need for tracheostomy. No differences
were found in the ratio of the other complications during
the first 24 h and the first month. Long-term complications
were reported in all patients. Those cases without family
aggregation presented a trend of higher rate for mechanical,
nephrological, hematological, endocrine, and infectious
complications (Supplementary Table 5). Survival after
transplantation according to family aggregation is represented
in Figure 2B.
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TABLE 4 | Long-term complications after lung transplant.
All patients (n = 20) With telomere
shortening (n = 12)
Without telomere
shortening (n = 8)
P-value
>1 complication after transplant (n, %)* (n = 20) 18 (90.0) 11 (91.7) 7 (87.5) 1.000
Post-operative complications in the first 24 h (n, %) 18 (90.0) 10 (83.3) 8 (100) 0.495
Complications during the first month (n, %) 17 (89.5) 9 (81.9) 8 (100) 0.485
Complications after the first month (n, %) (n = 19) 18 (94.7) 11 (100) 7 (87.5) 0.421
Allograft dysfunction (n, %) 8 (42.1) 3 (27.3) 5 (62.5) 0.181
Nephrological complications (n, %) 7 (35.0) 4 (33.3) 3 (37.5) 1.000
Positive pre-transplant CMV serology (n, %) 18 (90.0) 11 (91.7) 7 (87.5) 1.000
Post-transplant CMV replication (n, %) (n = 19) 14 (73.7) 7 (63.6) 7 (87.5) 0.338
Hematological alterations due to CMV treatment (n, %) (n = 15) 4 (26.7) 3 (33.3) 1 (16.7) 0.604
CMV negativity after treatment (n, %) (n = 16) 9 (56.2) 4 (44.4) 5 (71.4) 0.358
Infectious complications (n, %) 12 (60.0) 6 (50.0) 6 (75.0) 0.373
Hematological complications (n, %) 6 (30.0) 4 (33.3) 2 (25.0) 1.000
Endocrine complications (n, %) 15 (75.0) 8 (66.7) 7 (87.5) 0.603
Hospital admissions after transplant [median (Q1;Q3)] (n = 19) 1.0 (0.00;3.00) 2.00 (1.00;3.00) 0.00 (0.00;1.25) 0.033
* >1 complication at any time after lung transplant.
TABLE 5 | Post-transplant complications according to telomere dysfunction and time after lung transplantation.













Endocrine (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 8 (67) 7 (88)
Post-transplant CMV replication (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (58) 7 (88)
Infectious (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (50) 6 (75)
Allograft dysfunction (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (25) 5 (62)
Hemodynamic dysfunction (n, %) 4 (33) 3 (38) 3 (25) 3 (38) 0 (0.0) 0 (0.0)
Hematological (n, %) 4 (33) 0 (0.0) 2 (17) 0 (0.0) 4 (33) 2 (25)
Mechanical (n, %) 3 (25) 3 (38) 2 (17) 3 (38) 0 (0.0) 0 (0.0)
Primary graft dysfunction (n, %) 2 (17) 1 (12) 2 (17) 1 (12) 0 (0.0) 0 (0.0)
Donor lung infection (n, %) 0 (0.0) 1 (12) 0 (0.0) 1 (12) 0 (0.0) 0 (0.0)
Atrial fibrillation (n, %) 2 (17) 0 (0.0) 1 (8) 0 (0.0) 0 (0.0) 0 (0.0)
Renal (n, %) 1 (8) 1 (12) 0 (0.0) 0 (0.0) 4 (33) 3 (38)
Miopathy of critical patient (n, %) 1 (8) 0 (0.0) 1 (8) 0 (0.0) 0 (0.0) 0 (0.0)
DISCUSSION
Previous studies have analyzed LT morbidity and mortality
in patients with telomere abnormalities with controversial
results (19–25). Our study reveals for the first time a long-
term positive LT outcome in overall fibrotic ILD population
regardless of telomere dysfunction. Furthermore, we report
the order in appearance and the frequency of the subsequent
complications according to elapsed time from transplantation
and presence of telomere dysfunction. Therefore, while a
higher rate of LT complications has previously been reported
in patients with telomeropathy (19–25), our study highlights
the long-term benefits of LT despite telomere dysfunction
by optimizing the knowledge and the management of
transplant morbidity.
Our main finding was the benefit of LT in survival of fibrotic
ILD regardless of telomere dysfunction. We report a good
LT outcome in the overall study population with a survival
rate >80% and a similar post-transplant follow-up. Previous
studies have also evaluated the impact of transplantation for
pulmonary fibrosis in ILD patients carrying telomere disorders.
Swaminathan et al. reported a significantly higher risk of death
for patients carrying variants in TERT, RTEL1, or PARN (25);
while Newton et al. showed the association between telomere
length below the 10th percentile and worse post-transplant
survival (23). Although this poor outcomewas related to systemic
complications of telomere dysfunction, Borie et al. reported no
differences in survival between controls and telomerase mutation
carriers with higher risk for hematological complications (21).
Similarly, Silhan et al. also described a reasonable post-transplant
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Infectious cause Other causes
PATIENTS WITHOUT TELOMERE SHORTENING
1 Yes 75–50th Not tested 1 Urinary sepsis None
2 No 50–25th Not tested 1 Lower right lobe pneumonia (P.
aeruginosa)
None
3 No 50–25th Not tested 1 Respiratory infection (Rhinovirus) CLAD
PATIENTS WITH TELOMERE SHORTENING
4 No <25th TERT 1 None Cervical lymphadenectomy (M1
squamous cell carcinoma of
unknown primary origin)
5 Yes <25th TERT 3 Respiratory infection (MRSA)
Empyema (S.aureus)
Suspected unconfirmed CLAD
6 No <25th RTEL1 3 Acute gastroenteritis
Elbow abscess
Influenza A virus infection
None
7 Yes <25th DKC1 3 CMV viremia
Lower right lobe pneumonia +
non-complicated
parapneumonic pleural effusion
Fever of unknown origin
8 No <10th RTEL1 1 None CLAD
9 No <10th Not found 2 None Pulmonary embolism
Cervix squamous cell carcinoma
stage IIIB
10 No <10th RTEL1 3 Respiratory infection (Respiratory
syncytial virus)
Bacteremia (P.aeruginosa)
Influenza b virus infection
None
11 No <1th DKC1 6 Respiratory infection (x2)
Perianal condylomatosis
Acute ILD exacerbation in native
lung
ILD progression in native
lung (X2)




survival despite a higher rate of post-transplant complications
(20). In addition, LT feasibility was also assessed for other
telomeropathies like dyskeratosis congenital (45) and in the case
of multiple solid organ transplantation (46) with a favorable
long-term post-transplant outcome.
The controversial results reported so far are probably due
to a wide dispersion of methods and lack of control group in
most studies (19–25). Moreover, a broad variety of transplant
centers were involved in the previous studies with great
heterogeneity of national organ transplant programs and center-
specific pre-surgical, surgical, and post-surgical procedures. Very
few randomized studies have been conducted in LT for the
general population leaving some topics with a lack of evidence
and outcomes far from optimal for many patients (47). Hence,
making decisions in LT is sometimes highly controversial and
requires an evidence-experience balance. Considering these
arguments, we prospectively assessed LT outcomes according to
telomere dysfunction as the only differential biological marker
among recipients in our single-transplantation center cohort. No
differences were found in pre-transplant functional status for the
overall study population despite the younger mean age of the
telomere dysfunction group of patients, the fibrotic ILD and/or
the pre-transplant treatment prescription.
An important issue when considering survival is to investigate
the quality of patient survival. Although morbidity and mortality
have previously been assessed in fibrotic ILD with telomeropathy
(20–25), knowledge is lacking about outcomes in terms of quality
of life. Our study describes for the first time the post-transplant
benefits in quality of life despite telomere disorders and their
complications. The enhancement of post- transplant quality of
life was reported for the overall study population through the
improvement of ATAQ and K-BILD scores and the feasibility for
independent and active life with oxygen withdrawal. Hence, our
study shows quality of life gains for transplanted ILD patients
regardless of telomere dysfunction.
However, this favorable effect needs to be balanced
with the higher rate of post-transplant morbidity reported
for telomeropathies. Therefore, our research thoroughly
investigates the morbidity profiles according to elapsed time
from transplantation. The post-transplant appearance and
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FIGURE 2 | (A) Post-transplant survival according to presence or absence of telomere dysfunction. Patients with telomere dysfunction had a greater post-transplant
follow up period due to an earlier requirement of lung transplant after pulmonary fibrosis diagnosis. As previously described in Table 2, a shorter time from diagnosis
to transplantation was reported for patients with telomere dysfunction. (B) Survival after lung transplant according to family aggregation. A worse post-transplant
survival was reported for family aggregation patients group during the first year. However, at 24 months, post-transplant survival was ≤50% regardless of family
aggregation. Since genetic studies have not yet been implemented in routine clinical practice in most centers, further studies are needed to evaluate family
aggregation as an outcome predictor regardless of the underlying genetic defect.
FIGURE 3 | Post-transplant FVC (L) models. We analyzed the impact in post-transplant FVC of the following variables: the pre-transplant FVC, the age at the time of
lung transplantation and the absence of telomere dysfunction and pulmonary fibrosis family aggregation. A statistically significant impact in post-transplant FVC was
reported for pre-transplant FVC and the absence of family aggregation. The absence of telomere dysfunction did not statistically impact in post-transplant FVC.
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TABLE 7 | Quality of life after lung transplant.
All patients (n = 20) With telomere
shortening (n = 12)
Without telomere
shortening (n = 8)
P-value
Post-transplant FVC [ L, mean (SD)] 2.42 (0.77) 2.31 (0.51) 2.57 (1.05) 0.524
Post-transplant FVC [%, mean (SD)] 60.4 (17.6) 53.0 (12.7) 70.4 (19.0) 0.045
Post-transplant ATAQ score [mean (SD)] 58.2 (12.9) 60.6 (15.0) 54.7 (9.16) 0.333
Post-transplant K-BILD score [mean (SD)] 60.1 (9.14) 60.1 (9.66) 60.0 (9.10) 0.983
Oxygen withdrawal after transplantation (n, %) 16 (94.1) 9 (90.0) 7 (100) 1.000
Independence for daily life activities after transplantation (n, %) 15 (88.2) 9 (90.0) 6 (85.7) 1.000
Active life after transplantation (n, %) 11 (64.7) 6 (60.0) 5 (71.4) 1.000
Independence for daily life activities: feeding, personal hygiene and dressing tasks without help. Active life: to be able to return to work and/or hobbies.
predominance of complications could be chronological and
change according to successive clinical requirements after
transplantation and patient susceptibility. Telomere dysfunction
is associated with immunodeficiency (28) and poor outcomes
of immunosuppressive drugs (26, 27). Thereby, it could explain
our higher rate of hospital admissions after transplantation
for the telomere dysfunction group due to a wide variety of
infections. The post-transplant antibiotic prophylaxis in these
cases is a hypothesis that still needs to be evaluated. The CMV
post-transplant prophylaxis performed could explain a similar
rate of CMV relapsing viremia in those cases with or without
telomere dysfunction, deviating from previous reports (24).
Although a similar effect, CMV prophylaxis toxicity was mainly
reported in telomere dysfunction cases as thrombocytopenia or
leukopenia. Hematological complications are highly associated
with telomeropathy (20, 21) and may complicate further due
to ECC in the early post-transplant period and long-term
drug toxicities.
The main limitations of the present study are the small sample
size of our series and the lack of a validation cohort. However,
LT experience and protocols may differ among centers, which
represents a major difficulty for homogeneously increasing the
number of cases or finding a proper validating cohort with
patients screened for telomere length at diagnosis.
Hence, increasing the knowledge about when and why
each complication appears would set specific prevention and
management strategies in order to tip the balance in favor of
survival benefits. Pre-transplant work-up considerations should
include telomere disorders in order to establish variations
in care (48). However, wider evidence is clearly needed
to identify interventions that work best for this subset of
ILD patients.
In conclusion, our results support the survival gains of lung
transplant regardless of telomere disorders.
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